17th Mar 2014 12:56
LONDON (Alliance News) - GW Pharmaceuticals PLC said Monday that it has continued to make progress with its cannabinoid pipeline, as it provided an update on the progress of several of its pipeline products.
The company completed a Phase I clinical trial of candidate GWP42006 to treat epilepsy; the company said that there were no serious or severe adverse events, and no significant side effects were observed. The company expects to begin a Phase 2 study with the treatment later in 2013. It has also received a patent for the use of the treatments ingredient, non-psychoactive cannabinoid cannabidivarin, for the treatment of epilepsy.
The company has begun a twelve week Phase 2b study for candidate GWP42004 to treat Type 2 diabetes. It expects this study to be completed in the second half of 2015. It also commenced a Phase 2a trial using candidate GWP42003 to treat schizophrenia. This study is expected to be completed in the second-half of the 2015.
Additionally, the company expects Phase 3 study data for its treatment Sativex, used to treat cancer pain, towards the end of 2014. It also expects to commence a Phase 3 trial for Sativex in the treatment of Multiple-sclerosis spasticity in the second half of 2014.
"As GW continues to progress its clinical work with cannabinoids, our pipeline has the potential to yield, as it did with Epidiolex, a flow of exciting new product candidates in a wide variety of therapeutic areas," said Director of Research and Development Stephen Wright in a statement.
Shares in GW were trading up 0.3% at 385.06 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L